Miranda M.C. van der Lee

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts et al. · Molecular Pharmaceutics · 2015 · 219 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 215 citations

Pharmacy, Oncology, Pharmacology +16

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

Jonathan Black, Gulden Menderes, Stefania Bellone et al. · Molecular Cancer Therapeutics · 2016 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines

Ruud G. E. Coumans, G.J.A. Ariaans, Henri Spijker et al. · Bioconjugate Chemistry · 2020 · 56 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmaceutics +17

β-Arrestin Recruitment Assay for the Identification of Agonists of the Sphingosine 1-Phosphate Receptor EDG1

Miranda M.C. van der Lee, Maaike Bras, Chris J. van Koppen et al. · SLAS DISCOVERY · 2008 · 54 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17